Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke.

MLA

Zhu, Zhengbao, et al. “Plasma Osteopontin Levels and Adverse Clinical Outcomes after Ischemic Stroke.” Atherosclerosis, vol. 332, Sept. 2021, pp. 33–40. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2021.07.010.

APA

Zhu, Z., He, Y., Shi, M., Guo, D., Zhang, K., Ren, L., Peng, Y., Yang, P., Chen, J., Zang, Y., Wang, A., Xu, T., Li, Q., Ju, Z., Geng, D., Zhang, Y., & He, J. (2021). Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis, 332, 33–40. https://doi.org/10.1016/j.atherosclerosis.2021.07.010

Chicago

Zhu, Zhengbao, Yan He, Mengyao Shi, Daoxia Guo, Kaixin Zhang, Liyun Ren, Yanbo Peng, et al. 2021. “Plasma Osteopontin Levels and Adverse Clinical Outcomes after Ischemic Stroke.” Atherosclerosis 332 (September): 33–40. doi:10.1016/j.atherosclerosis.2021.07.010.